Immunohistochemical assessment of primary breast tumors and metachronous brain metastases, with particular regard to differences in the expression of biological markers and prognosis.

In this study, we conducted an immunohistochemical analysis of primary breast tumors and metachronous brain metastases to compare the differences in the expression of biological markers between the two. Carcinoma tissues from primary breast tumors and metachronous brain metastases collected from 21 patients were examined immunohistochemically for the expression status of the estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor (HER)-2, Ki-67, bcl-2 and p53, and the results were compared. In addition, the relationships between the expression of these factors and prognosis were evaluated. There were no significant differences in the frequencies of ER-, PgR-, HER-2-, bcl-2- or p53-positivity between the primary breast tumors and metachronous brain metastases. While the Ki-67 labeling index (LI) was high in both the primary breast tumors and brain metastases, it was significantly higher in the brain metastases than in the corresponding primary breast tumors (P=0.003). With regard to the prognosis, breast cancer patients who showed ER-positivity in the primary tumors showed significantly longer survival after primary diagnosis (P=0.0076). Furthermore, breast cancer patients who exhibited ER-positivity, bcl-2-positivity or p53-negativity in the primary tumors showed significantly longer intervals from primary diagnosis to the detection of the brain metastases. Of all the markers, only the Ki-67 LI was significantly higher in the brain metastases than in the primary breast tumors. We confirmed that the tumor characteristics were worse in the metachronous brain metastases.

[1]  Meenakshi Singh,et al.  Her-2/neu status in breast cancer metastases to the central nervous system. , 2009, Archives of pathology & laboratory medicine.

[2]  C. Tripodo,et al.  Lymph node metastases displaying lower Ki-67 immunostaining activity than the primary breast cancer. , 2006, Anticancer research.

[3]  Raymond R Tubbs,et al.  Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR , 2006, The American journal of surgical pathology.

[4]  P. Andersen,et al.  Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy , 2005, Breast Cancer Research and Treatment.

[5]  F. André,et al.  Risk factors for brain relapse in patients with metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Vincent-Salomon,et al.  Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases. , 2004, Anticancer research.

[8]  S. Pinder,et al.  Brain metastases from breast cancer: identification of a high-risk group. , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

[9]  M. Ellis,et al.  Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. , 2003, Cancer research.

[10]  J. Engel,et al.  Determinants and prognoses of locoregional and distant progression in breast cancer. , 2003, International journal of radiation oncology, biology, physics.

[11]  T. Aas,et al.  Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. , 2003, European journal of cancer.

[12]  W. Lichtenegger,et al.  HER2 in brain metastases: issues of concordance, survival, and treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  V. Anaf,et al.  Ki-67 Immunostaining Activity is Higher in Positive Axillary Lymph Nodes than in the Primary Breast Tumor , 2002, Breast Cancer Research and Treatment.

[14]  D. D. Maki,et al.  Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. , 2000, AJNR. American journal of neuroradiology.

[15]  G. Pelosi,et al.  Ki‐67 immunostaining in 322 primary breast cancers: Associations with clinical and pathological variables and prognosis , 1997, International journal of cancer.

[16]  J. Coindre,et al.  Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. , 1996, British Journal of Cancer.

[17]  W. Hiddemann,et al.  Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  I. Ellis,et al.  Immunocytochemical localization of fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy , 1994, International journal of cancer.

[19]  J. Farndon,et al.  Correlation between p53 mutations and antibody staining in breast carcinoma , 1993, The British journal of surgery.

[20]  S. Nordling,et al.  Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. , 1993, British Journal of Cancer.

[21]  P. Lampertico,et al.  Proliferation index as a prognostic marker in breast cancer , 1993, Cancer.

[22]  H. J. Evans,et al.  p53 allele losses, mutations and expression in breast cancer and their relationship to clinico‐pathological parameters , 1992, International journal of cancer.

[23]  S. Friend,et al.  Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[25]  S. Shibata,et al.  Immunohistochemical expression of E-cadherin in metastatic brain tumors , 2006, Brain Tumor Pathology.

[26]  S. Rodella,et al.  Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma , 2005, Breast Cancer Research and Treatment.

[27]  S. Chevillard,et al.  Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer , 2005, Breast Cancer Research and Treatment.

[28]  S. Pinder,et al.  Original Article Brain Metastases from Breast Cancer: Identification of a High-risk Group , 2004 .

[29]  T. Petit,et al.  Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. , 2004, European journal of cancer.

[30]  S. Nordling,et al.  Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. , 1997, Acta oncologica.

[31]  I. Ellis,et al.  Immunocytochemical localization of BCL‐2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy , 1994, International journal of cancer.